KRAS and Hyperbilirubinemia: To our knowledge, this is the first substantial study to examine the association between quantitative analysis of hepatic enhancement by Gd-EOB-DTPA–enhanced MR imaging and the prediction of NS3/4A inhibitor–induced hyperbilirubinemia.